Ramaprasad Srinivasan, MD, PhD, discusses the challenges of developing new therapies to treat patients with rare renal cell carcinoma subtypes.
Ramaprasad Srinivasan, MD, PhD
Advertisement
Articles by Ramaprasad Srinivasan, MD, PhD
Ramaprasad Srinivasan, MD, PhD, staff clinician, Urologic Oncology Branch, National Cancer Institute, discusses the need for targeted therapies for patients with non-clear cell renal cell carcinoma (RCC) and the types of agents these patients are likely benefit to from.
Advertisement
Latest Updated Articles
Dr. Srinivasan on Targeted Therapies for Non-Clear Cell RCCPublished: February 23rd 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5